ZBH

Business profile & competitive position

Zimmer Biomet Holdings, Inc. operates in the Healthcare sector, specifically the Medical – Devices industry. The company designs, manufactures and markets orthopedic reconstructive products, sports medicine and biologics offerings, extremities and trauma products, craniomaxillofacial and thoracic products, bone cement, surgical products, and integrated digital and robotic technologies that use data, analytics and artificial intelligence. At its core, Zimmer Biomet sells hardware and enabling technology for bones, joints and supporting soft tissues, working closely with surgeons and healthcare providers around the world.

The financial footprint is consistent with a capital-intensive, inventory-heavy medical-device franchise, not a high-margin, asset-light technology name. Net margin is 9.5% and return on equity is 6.4%. An ROE of 6.4% suggests the business is not generating exceptionally high returns on the book equity it employs, while a 9.5% net margin points to decent but not dominant pricing power. One structural feature that helps explain this is the company’s consignment sales model: consignment sales represented approximately 85% of net sales in 2025. That model keeps inventory close to the customer before it is formally sold, which can support recurring surgical volume but also ties up working capital and limits margin expansion compared with pure cash-up-front device sales.

The company also carries a low beta of 0.47, meaning the stock has historically moved less than half as much as the broader equity market. That is consistent with a mature, healthcare defensive business tied to elective-procedure demand rather than cyclical growth. As of December 31, 2025, Zimmer Biomet employed approximately 2,000 research and development employees worldwide, indicative of ongoing investment in product refresh but not at the scale of a mega-cap med-tech leader.

Financial posture

As of the current snapshot, Zimmer Biomet trades at $91.57 with a market capitalization of $17.7 billion and a trailing price-to-earnings ratio of 22.2. A P/E of 22.2 implies an earnings yield of roughly 4.5%, which sits in the middle ground for a large-cap healthcare name: cheaper than high-growth med-tech or biotech peers, but not obviously discounted relative to its single-digit net margin and modest ROE. The RSI is 45.4, essentially neutral, and the stock is slightly below its 50-day exponential moving average of $93.89, suggesting near-term price action has been soft rather than stretched.

Profitability metrics paint the same picture: a 9.5% net margin and a 6.4% ROE. Those figures do not scream wide economic moat, but they are also not distressed. The beta of 0.47 confirms low volatility versus the market, which often attracts income-and-defense-oriented investors. With the company paying a quarterly dividend—most recently $0.24 per share according to the September 28 headline—the low-beta profile aligns with a shareholder base that values stability and cash return over rapid expansion.

Strategic priorities & outlook

Zimmer Biomet’s most recent 10-K filing describes four near-term operational priorities. First, the company aims to rapidly commercialize new data solutions, surgical techniques, innovative materials, biologics products, and implant and instrument designs. Second, it plans to broaden its offerings in certain product categories and to explore new technologies, including artificial intelligence and machine learning. Third, it intends to continue identifying innovative technologies through acquisitions, licensing arrangements and strategic alliances. Fourth, it is executing a multi-year initiative to convert substantial portions of the U.S. sales force from independent sales agents to employees.

That last point is especially relevant for investors watching margins and execution risk. Shifting a large U.S. sales force from independent agents to employees changes compensation, control and fixed-cost structure. It may eventually improve training, account management and adoption of new products, but the transition can create near-term sales disruption and expense pressure.

The 10-K also highlights important geographic concentration. In 2025, the U.S. accounted for roughly 95% of Americas segment net sales, while Japan accounted for roughly 50% of Asia Pacific net sales. That makes the Americas segment highly dependent on the U.S. healthcare reimbursement environment, and the Asia Pacific segment unusually exposed to Japanese procedure volumes and currency translation. The 85% consignment-sales ratio further ties reported revenue to actual surgical utilization, so a slowdown in joint-replacement volumes would flow through the top line quickly.

Macro & geopolitical exposure

As a Medical – Devices company, Zimmer Biomet sits at the intersection of healthcare regulation, reimbursement policy, trade and demographics. The most relevant macro exposures for this industry include FDA product approvals and facility inspections, CMS and private-payer reimbursement rates for orthopedic procedures, and product-liability litigation risk. Any material change in Medicare reimbursement for knee or hip replacements, for example, could alter the economics of the reconstructive market.

Trade policy is also relevant. The company sources and sells globally, so tariffs on steel, titanium, polymers or finished devices can affect both input costs and pricing power. Currency movements matter because roughly 95% of Americas sales are U.S.-based and roughly 50% of Asia Pacific sales are Japan-based; a stronger yen helps reported Asia Pacific revenue, while dollar strength elsewhere can compress translated earnings. Supply-chain resilience for specialized implants and instruments is another watch item, as is the longer-term demographic tailwind of aging populations in developed markets, which generally supports demand for joint replacement over time.

Recent developments

The most recent headlines around Zimmer Biomet have been company-specific rather than event-driven. On September 28, 2026, Defense World reported that shareholders are set to receive a $0.24 quarterly dividend. On September 24, 2026, Defense World noted that State Street Corp had lifted its stake in ZBH. Earlier in the month, on September 17, 2026, Zacks published a piece titled “Here’s Why Zimmer Biomet (ZBH) is a Strong Value Stock.” On September 10, 2026, Defense World ran a comparison between Zimmer Biomet and CapsoVision. None of these items changed the corporate structure or issued guidance, but they reflect ongoing income and institutional-ownership narratives that often surround a mature dividend-paying med-tech stock.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Zimmer Biomet has beaten the earnings estimate seven times, with the data source recording a 100% beat rate. The average earnings surprise across those quarters is 3.2%, and the average five-day price move after earnings has been +2.57%, classified as an upward drift. On the surface that suggests a reliable beat-and-drift pattern, but the actual quarter-by-quarter price action shows the relationship is much messier than a simple “beat means up” rule.

The most recent four reports show the disconnect clearly. On August 5, 2026, ZBH reported $2.07 versus a $2.01 estimate, a 3% positive surprise, yet the stock fell 0.99% the next day and 0.28% over the following five days. On April 28, 2026, the company delivered a much larger 12.4% beat, with actual EPS of $2.09 against an estimate of $1.86, and the stock still dropped 3.3% the next day, though it eked out a 0.25% gain over the subsequent five days. By contrast, the February 10, 2026 quarter, a modest 1.7% beat ($2.42 versus $2.38), produced a 4.61% next-day gain and a 7.49% five-day gain. The November 5, 2025 quarter, a 1.6% beat ($1.90 versus $1.87), saw a 1.1% next-day move and a 2.83% five-day move.

What that means for post-earnings analysis is that the average five-day drift of +2.57% hides wide dispersion. A strong beat can be sold into, and a modest beat can ramp. The unofficial consensus going into the next report, scheduled for November 4, 2026 before the market open, stands at $1.88 per share. The data shows that beating that number has not guaranteed a positive immediate price reaction, so interpreting the event requires more than comparing actual EPS to the market’s real expectation.

For a deeper dive into how institutional analysts, hedge funds and quant models currently weigh these factors, review the full institutional verdict and consensus picture on the ticker page.